About Merus N.V.
https://www.merus.nlMerus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.
CEO
Sven Ante Lundberg
Compensation Summary
(Year 2021)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Most Recent Analyst Grades
B of A Securities
Buy
BMO Capital
Outperform
Wells Fargo
Equal Weight
Barclays
Equal Weight
Leerink Partners
Market Perform
LifeSci Capital
Market Perform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
PARADIGM BIOCAPITAL ADVISORS LP
Shares:4.37M
Value:$393.64M
AVORO CAPITAL ADVISORS LLC
Shares:3.54M
Value:$318.82M
COMMODORE CAPITAL LP
Shares:3.52M
Value:$317.25M
Summary
Showing Top 3 of 284
About Merus N.V.
https://www.merus.nlMerus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $10.37M ▲ | $92.2M ▲ | $-81.55M ▲ | -786.17% ▲ | $-1.26 ▲ | $-76.04M ▲ |
| Q2-2025 | $7.49M ▼ | $21.44M ▲ | $-134.33M ▼ | -1.79K% ▼ | $-2.23 ▼ | $-93.15M ▼ |
| Q1-2025 | $24.48M ▲ | $20.44M ▼ | $-89.17M ▼ | -364.22% ▼ | $-1.4 ▼ | $-69.47M ▲ |
| Q4-2024 | $8.82M ▼ | $86.26M ▲ | $-29.85M ▲ | -338.33% ▲ | $-0.45 ▲ | $-85.01M ▼ |
| Q3-2024 | $10.57M | $69.01M | $-89.72M | -848.67% | $-1.46 | $-64.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $542.95M ▼ | $771.99M ▼ | $110.36M ▼ | $661.63M ▼ |
| Q2-2025 | $710.22M ▲ | $980.18M ▲ | $138.44M ▲ | $841.74M ▲ |
| Q1-2025 | $458.32M ▼ | $730.92M ▼ | $134.8M ▲ | $596.12M ▼ |
| Q4-2024 | $537.03M ▼ | $785.13M ▼ | $134.77M ▼ | $647.93M ▼ |
| Q3-2024 | $632.27M | $844.68M | $141.41M | $703.26M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-95.52M ▲ | $-84.92M ▼ | $329K ▲ | $6.13M ▼ | $-75.3M ▼ | $-85.25M ▼ |
| Q2-2025 | $-158.22M ▼ | $-69.23M ▲ | $-7.46M ▲ | $333.28M ▲ | $245.63M ▲ | $-69.32M ▲ |
| Q1-2025 | $-96.47M ▼ | $-96.46M ▼ | $-8.71M ▲ | $6.74M ▼ | $-96.14M ▲ | $-96.63M ▼ |
| Q4-2024 | $-30.92M ▲ | $-66.66M ▲ | $-77.7M ▲ | $8.07M ▼ | $-139.74M ▲ | $-66.68M ▲ |
| Q3-2024 | $-99.91M | $-80.42M | $-133.67M | $10.89M | $-196.46M | $-80.69M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Sven Ante Lundberg
Compensation Summary
(Year 2021)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Most Recent Analyst Grades
B of A Securities
Buy
BMO Capital
Outperform
Wells Fargo
Equal Weight
Barclays
Equal Weight
Leerink Partners
Market Perform
LifeSci Capital
Market Perform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
PARADIGM BIOCAPITAL ADVISORS LP
Shares:4.37M
Value:$393.64M
AVORO CAPITAL ADVISORS LLC
Shares:3.54M
Value:$318.82M
COMMODORE CAPITAL LP
Shares:3.52M
Value:$317.25M
Summary
Showing Top 3 of 284